A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects

Pfizer

Status and phase: Withdrawn; Phase 1

Conditions: Obesity

Treatments: Drug: PF 05212389 or placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01472848

B2201010

Details and patient eligibility

About

This study examines whether a gradual increase of dose improves the gastrointestinal tolerability (nausea and vomiting) of PF05212389

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Obesity

Exclusion criteria

Diabetes mellitus (type 1 or type 2) Heart failure Eating disorders Psychiatric disorders History of suicide attempt History of pancreatitis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

0 participants in 6 patient groups

Cohort 1

Experimental group

Treatment:

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Cohort 2

Experimental group

Treatment:

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Cohort 3

Experimental group

Treatment:

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Cohort 4

Experimental group

Treatment:

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Cohort 5

Experimental group

Treatment:

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Cohort 6

Active Comparator group

Treatment:

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo

Drug: PF 05212389 or placebo